Wallis and Futuna, 2014

JRF (data for 2014) not submitted; 2012 data used

**Population**

<table>
<thead>
<tr>
<th>Total population*</th>
<th>13 206</th>
</tr>
</thead>
<tbody>
<tr>
<td>Births</td>
<td></td>
</tr>
<tr>
<td>National Immunization Programme (NIP) target</td>
<td></td>
</tr>
</tbody>
</table>


**Finance**

- Gross national income per capita* (US $)
- Line item in budget for vaccines
- % of vaccines in routine immunization funded by government
- % of routine immunization - funded by government
- Eligible for GAVI support

* World Health Statistics 2015

**Immunization schedule**

- DTP-HepB-IPV: M2, M3, M4, M16
- HepB: B, M1, M6
- Pneumo_conj: M2, M4, M12
- MMR: M12, M18

B=birth, W=week, M=month, Y=year

**GVAP and WPRO framework indicators, 2014**

- Polio-free status sustained* Yes
- At least one dose of IPV introduced by end of 2015* Yes
- Country validated as having achieved MNT elimination* Yes
- Country verified for measles elimination by 2015* No
- Seroprevalence of chronic hepatitis B infection (HBsAg) reduced to <1% in 5 year olds by 2017* 0.4% (2012)
- Rubella-containing vaccine introduced* Yes
- Rubella case-based data submitted to WPRO* Yes
- At least one new or underutilized vaccine introduced since 2010* Yes
- DTP3 national immunization coverage >95% by 2020 No data
- DTP3 >90% coverage in all districts (proportion of districts with >90% coverage) No data
- DTP3 dropout rate <5% No data
- Increasing trend in domestic expenditure since 2010 No data
- NITAG established No data

* 2015 data

**NIP priority needs**

No data

**Reported cases**

<table>
<thead>
<tr>
<th>Year</th>
<th>Non-polio AFP rate</th>
<th>% adequate specimens</th>
<th>Cases</th>
<th>IR</th>
<th>Cases</th>
<th>IR</th>
<th>Cases</th>
<th>IR</th>
<th>Cases</th>
<th>IR</th>
<th>Cases</th>
<th>IR</th>
</tr>
</thead>
<tbody>
<tr>
<td>2005</td>
<td>1.0</td>
<td>0%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2006</td>
<td>0.0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2007</td>
<td>0.0</td>
<td></td>
<td>0</td>
<td>0.0</td>
<td>0</td>
<td>0.0</td>
<td>0</td>
<td>0.0</td>
<td>0</td>
<td>0.0</td>
<td>0</td>
<td>0.0</td>
</tr>
<tr>
<td>2008</td>
<td>0.0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2009</td>
<td>0.0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2010</td>
<td>0.0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2011</td>
<td>0.0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2012</td>
<td>0.0</td>
<td></td>
<td>0</td>
<td>0.0</td>
<td>0</td>
<td>0.0</td>
<td>0</td>
<td>0.0</td>
<td>0</td>
<td>0.0</td>
<td>0</td>
<td>0.0</td>
</tr>
<tr>
<td>2013</td>
<td>0.0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2014</td>
<td>0.0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Non-polio AFP rate = incidence per 100 000 unimmunized under 15 years; % adequate specimens = % of AFP cases with 2 specimens within 14 days of paralysis onset.

IR = incidence rate: for measles and rubella, per 1 000 000 population; for neonatal tetanus, per 1000 live births; for all others, per 100 000 population. Total tetanus includes neonatal tetanus cases.

Population source: United Nations, Department of Economic and Social Affairs, Population Division: World Population Prospects

**Reported immunization coverage, 2005–2014**

**Reported immunization coverage, 2010–2014**

**NICP and WPRO framework indicators, 2014**

- Polio-free status sustained* Yes
- At least one dose of IPV introduced by end of 2015* Yes
- Country validated as having achieved MNT elimination* Yes
- Country verified for measles elimination by 2015* No
- Seroprevalence of chronic hepatitis B infection (HBsAg) reduced to <1% in 5 year olds by 2017* 0.4% (2012)
- Rubella-containing vaccine introduced* Yes
- Rubella case-based data submitted to WPRO* Yes
- At least one new or underutilized vaccine introduced since 2010* Yes
- DTP3 national immunization coverage >95% by 2020 No data
- DTP3 >90% coverage in all districts (proportion of districts with >90% coverage) No data
- DTP3 dropout rate <5% No data
- Increasing trend in domestic expenditure since 2010 No data
- NITAG established No data

* 2015 data

**NIP priority needs**

No data

**Reported cases**

<table>
<thead>
<tr>
<th>Year</th>
<th>Non-polio AFP rate</th>
<th>% adequate specimens</th>
<th>Cases</th>
<th>IR</th>
<th>Cases</th>
<th>IR</th>
<th>Cases</th>
<th>IR</th>
<th>Cases</th>
<th>IR</th>
<th>Cases</th>
<th>IR</th>
</tr>
</thead>
<tbody>
<tr>
<td>2005</td>
<td>1.0</td>
<td>0%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2006</td>
<td>0.0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2007</td>
<td>0.0</td>
<td></td>
<td>0</td>
<td>0.0</td>
<td>0</td>
<td>0.0</td>
<td>0</td>
<td>0.0</td>
<td>0</td>
<td>0.0</td>
<td>0</td>
<td>0.0</td>
</tr>
<tr>
<td>2008</td>
<td>0.0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2009</td>
<td>0.0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2010</td>
<td>0.0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2011</td>
<td>0.0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2012</td>
<td>0.0</td>
<td></td>
<td>0</td>
<td>0.0</td>
<td>0</td>
<td>0.0</td>
<td>0</td>
<td>0.0</td>
<td>0</td>
<td>0.0</td>
<td>0</td>
<td>0.0</td>
</tr>
<tr>
<td>2013</td>
<td>0.0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2014</td>
<td>0.0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Non-polio AFP rate = incidence per 100 000 unimmunized under 15 years; % adequate specimens = % of AFP cases with 2 specimens within 14 days of paralysis onset.

IR = incidence rate: for measles and rubella, per 1 000 000 population; for neonatal tetanus, per 1000 live births; for all others, per 100 000 population. Total tetanus includes neonatal tetanus cases.

Population source: United Nations, Department of Economic and Social Affairs, Population Division: World Population Prospects
**Planning**

- Multi-year plan (MYP)
- Annual workplan for immunization activities
  - Includes measles elimination activities
  - Includes hepatitis B control activities
  - Updated wild poliovirus importation and cVDPV response plan

**Safe immunization**

- % districts using auto-disable syringes
- System to monitor AEFI
  - Number of AEFI
- Disposal methods
- Vaccine AEFI review committee
- Injection safety review

**Measles elimination**

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Value</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Confirmed measles case rate* (per 1 million population)</td>
<td>0.0</td>
<td>Year of MCV1 introduction</td>
</tr>
<tr>
<td>Discarded as non-measles rate* (Target: ≥ 2 per 100 000 population)</td>
<td>0.0</td>
<td>Year of MCV2 introduction</td>
</tr>
<tr>
<td>% suspected cases with adequate specimens* (Target: ≥ 80%)</td>
<td>-</td>
<td>Year and target population of last SIA</td>
</tr>
</tbody>
</table>

* Data from measles monthly country reports to WHO

**Rubella**

- Rubella-containing vaccine in NIP: Yes
- Number of rubella cases (IgM positive): Not available
- Surveillance system for congenital rubella syndrome: Not available

**Percent of under-15 year population susceptible to measles and MCV1 coverage, 1999–2014**

- Not available

**Measles immunity profile, 2014**

- Not available

**Measles cases and immunization coverage, 1980–2014**

- ![Graph showing measles cases and coverage from 1980 to 2014]

**School-based immunization**

- Is there a school entry requirement?
  - If no, do schools check immunization status at enrolment?
  - What vaccines are required/checked?
  - At what school level/year?
  - Is routine vaccination given at school?
  - If yes, is this part of a comprehensive school-health program that delivers other health interventions?

**Coverage surveys**

- Year of most recent survey
- Type of survey
- Coverage results

**Operational indicators for hepatitis B control program**

- Year HepB vaccine first used in NIP: 1992
- Systems to monitor HepB vaccine birth dose
- Year HepB3 introduced nationwide
- Systems to deliver HepB vaccine birth dose
- Year HepB birth dose introduced
- No. of districts with >10% difference between DTP3-HepB3
- HepB vaccine birth dose coverage within 24 hours
- HepB vaccine third dose coverage

**Surveillance for Invasive Bacterial Vaccine-preventable Disease and Rotavirus**

<table>
<thead>
<tr>
<th>Disease</th>
<th>Type of surveillance system</th>
<th>Year surveillance started</th>
<th>Number of facilities under surveillance</th>
<th>Number of cases with positive tests</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rotavirus diarrhea</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bacterial meningitis</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bacterial pneumonia</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Note:** Unless otherwise specified, data are from the WHO/UNICEF Joint Reporting Forms (JRF) for Immunization